{"id":115,"date":"2023-01-27T15:20:03","date_gmt":"2023-01-27T15:20:03","guid":{"rendered":"http:\/\/43.143.235.42\/?page_id=115"},"modified":"2025-10-27T06:09:12","modified_gmt":"2025-10-27T06:09:12","slug":"%e5%8f%91%e8%a1%a8%e5%88%8a%e7%89%a9","status":"publish","type":"page","link":"https:\/\/www.yuemiaozhang.com\/?page_id=115","title":{"rendered":"\u53d1\u8868\u520a\u7269"},"content":{"rendered":"\n

\u8fd1\u4e94\u5e74\u5185\u7b2c\u4e00\/\u901a\u8baf\u4f5c\u8005\uff08\u542b\u5171\u540c\uff09\u53d1\u8868\u8bba\u6587\u60c5\u51b5\uff1a<\/strong><\/p>\n\n\n\n

2025\u5e74<\/strong><\/p>\n\n\n\n

Peng J, Zhang Y<\/strong>*, Wang J, Zhang H*, Schett G. Role of Chimeric Antigen Receptor-Expressing Cell Therapy in Immune-Mediated Kidney Diseases: A Review. Am J Kidney Dis<\/em><\/strong><\/em><\/strong>. 2025;86(3):360-371. (Review, IF 9.4)<\/p>\n\n\n\n

Dang S#, Zhang X#, Zhang Y<\/strong>*, Zhang H*. New thoughts on the intestinal microbiome-B cell-IgA axis and therapies in IgA nephropathy. Autoimmun Rev<\/em><\/strong><\/em><\/strong>. 2025;24(8):103835. (Review, IF 9.2)<\/p>\n\n\n\n

Wang J#, Xie T#, Peng J, Zhang Y<\/strong>*, Zhang H*. Characterizing the Real-World Risks of Kidney Injuries Associated with Chimeric Antigen Receptor T Cell Therapies-Evidence and Safety. Health Data Sci<\/em><\/strong><\/em><\/strong>.<\/strong> 2025;5:0325. (Article)<\/p>\n\n\n\n

Zhang Z#, Wang J#, Dang S#, Liu X, Zhang Y<\/strong>*, Zhang H. The worldview of Akkermansia muciniphila<\/em>, a bibliometric analysis. Front Microbiol<\/em><\/strong><\/em><\/strong>. 2025;16:1500893. (Review, IF 4.0)<\/p>\n\n\n\n

Wang J#, Xie T#, Zhang Y<\/strong>*, Zhang H*. The Cardiac and Renal Safety of Semaglutide in Patients with Type 2 Diabetes: A Real-World Study Based on FAERS. Cardiorenal Med<\/em><\/strong><\/em><\/strong>. 2025;15(1):413-422. (Article, IF 2.4)<\/p>\n\n\n\n

2024\u5e74<\/strong><\/strong><\/p>\n\n\n\n

Hu YT, Zhang YM<\/strong>*. Targeted release of budesonide in primary IgA nephropathy. The Lancet<\/em><\/strong><\/em><\/strong>, 2024, 403(10446): 2785. (Letter, Q1, IF= 98.4)<\/strong><\/p>\n\n\n\n

Wang J, Zhao W, Zhang Z, Liu X, Xie T, Wang L, Xue Y, Zhang Y<\/strong>*. A Journey of Challenges and Victories: A Bibliometric Worldview of Nanomedicine since the 21st Century. Adv Mater<\/em><\/strong><\/em><\/strong>. 2024;36(15):e2308915. (Article, Q1, IF= 27.4)<\/p>\n\n\n\n

Wang J, Zhang Z, Liu X, Shi S, Lv J, Zhang Y<\/strong>*, Zhang H. Exploring Novel Adverse Events of Nefecon. Kidney Int Rep<\/em><\/strong><\/em><\/strong>. 2024;9(9):2705-2717. (Article, Q1, IF= 5.7)<\/strong><\/p>\n\n\n\n

Wang L, Wang J, Zhang Y<\/strong>*, Zhang H. Current perspectives and trends of the research on hypertensive nephropathy: a bibliometric analysis from 2000 to 2023. Ren Fail<\/em><\/strong><\/em><\/strong>. 2024;46(1):2310122. (Article, Q1, IF= 3)<\/p>\n\n\n\n

Zhang YM<\/strong>, Zhang H. Current understanding and new insights in the treatment of IgA nephropathy. Nephrology<\/em><\/strong><\/em><\/strong>. 2024, Suppl 2:75-79. (Review, Q2, IF= 2.4)<\/strong><\/p>\n\n\n\n

2023\u5e74<\/strong><\/p>\n\n\n\n

Zhang YM<\/strong>#, Liu XZ#, Zhang Z, Zhou TC, Zhang X, Yang HY, Tan M, Hu N, Shi SF, Wang F, Xu R, Liu LJ, Wang SX, Liu G, Zhou FD, Zhao MH, Zhang H, Lv JC*, Zhang YP*, Zhang ZJ*, Yang L*. Clinicopathological and immunological features of new onset kidney disease: a rare event after SARS-CoV-2 vaccination. Natl Sci Rev<\/em><\/strong>. 2023;10(5):nwac034. (Article, Q1, IF= 23.178)<\/p>\n\n\n\n

Zhang YM<\/strong>#, Luo MT#, Wu Q, Wang YX, Ma X, Yan G, Zhang SH, Chen Y, Wan N, Zhang L, You D, Wei J*, Zhang ZJ*, Zhou TC*; Precise-CoVaccine study group. Long-term and effective neutralization against omicron sublineages elicited by four platform COVID-19 vaccines as a booster dose. Cell Discov<\/em><\/strong>. 2023;9(1):17.  (Research letter, Q1, IF = 38.09)<\/p>\n\n\n\n

Zhang YM<\/strong>, Lv JC, Wong MG, Zhang H, Perkovic V*. Glucocorticoids for IgA nephropathy-pro. Kidney Int<\/em><\/strong>. 2023;103(4):666-669. (Review, Q1, IF=19.00)<\/p>\n\n\n\n

Zhang YM<\/strong>#, Hu YT#, Lv JC, Zhang H. Corticosteroids in the treatment of IgA nephropathy: lessons from the TESTING trial. Pediatr Nephrol<\/em><\/strong>. 2023 Mar 7. (Review, Q2, IF= 3.65)<\/p>\n\n\n\n

2022<\/strong>\u5e74<\/strong><\/strong><\/p>\n\n\n\n

Zhang YM<\/strong>#, Ma XP#, Yan GH#, Wu Y#, Chen YL, Zhou ZM, Wan N, Su W, Liu FW, Dai MX, Yang M, Li CM, Yu XJ, Zhang L, Wang ZF*, Zhou TC*, You DY*, Wei J*, Zhang ZJ* on be half of the Precise-CoVaccine study group. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial. eClinicalMedicine<\/em><\/strong>.<\/em>2022 54:101680. (Article, Q1, IF= 17)<\/p>\n\n\n\n

Zheng J#*, Zhang YM<\/strong>#, Zhao HL#, Liu Y#, Baird D, Karim MA, Ghoussaini M, Schwartzentruber J, Dunham I, Elsworth B, Roberts K, Compton H, Molloy FM, Liu XZ, Wang L, Zhang H, Smith GD, Gaunt TR*. Multi-ancestry Mendelian randomization of omics traits revealing drug targets of COVID-19 severity. EBioMedicine<\/em><\/strong>. 2022; 81: 104112. (Article, Q1, IF= 11.205)<\/p>\n\n\n\n

Zhang YM<\/strong>#, Liu XZ#, Lin MM#, Zan JC#, Hu YT#, Wang XQ#, Wu WQ, Zhou TC, Lv JC*, Zhang H*, Yang L*, Zhang ZJ*. Immunosuppression impaired the immunogenicity of inactivated SARS-CoV-2 vaccine in non-dialysis kidney disease patients. J Infect<\/em><\/strong>. 2022;85(2):174-211. (Letter, Q1, IF= 38.637)<\/p>\n\n\n\n

Zheng J#*, Zhang YM<\/strong>#*, Rasheed H#, Walker V, Sugawara Y, Li J, Leng Y, Elsworth B, Wootton RE, Fang S, Yang Q, Burgess S, Haycock PC, Borges MC, Cho Y, Carnegie R, Howell A, Robinson J, Thomas LF, Brumpton BM, Hveem K, Hallan S, Franceschini N, Morris AP, K\u00f6ttgen A, Pattaro C, Wuttke M, Yamamoto M, Kashihara N, Akiyama M, Kanai M, Matsuda K, Kamatani Y, Okada Y, Walters R, Millwood IY, Chen Z, Davey Smith G, Barbour S, Yu C*, \u00c5svold BO*, Zhang H#*, Gaunt TR#*. Trans-ethnic Mendelian-randomization study reveals causal relationships between cardiometabolic factors and chronic kidney disease. Int J Epidemiol<\/em><\/strong>. 2022: 50(6):1995-2010. (Article, Q1, IF= 9.685)<\/p>\n\n\n\n

2021<\/strong>\u5e74<\/strong><\/strong><\/p>\n\n\n\n

Zhang Z#, Zhang G#, Guo M#, Tao W#, Liu X, Wei H, Jin T*, Zhang YM<\/strong>*, Zhu S*. The Potential Role of an Aberrant Mucosal Immune Response to SARS-CoV-2 in the Pathogenesis of IgA Nephropathy. Pathogens<\/em><\/strong>. 2021;10(7):881. (Article, Q2, IF= 4.531)<\/p>\n\n\n\n

Zhang YM<\/strong>, Zhou XJ, Wang YN, Liu XZ, Wang YF, Lau YL, Yang WL, Zhang H*. Shared genetic study gives insights into the shared and distinct pathogenic immunity components of IgA nephropathy and SLE. Mol Genet Genomics<\/em><\/strong>. 2021;296(4):1017-1026. (Article, Q3, IF= 2.980)<\/p>\n\n\n\n

Zhang YM<\/strong>#, Liu XZ#, Zhou XJ, Liu LJ, Shi SF, Hou P, Lv JC, Zhang H*. A Functional Variant rs3093023 in CCR6 Is Associated With IgA Nephropathy by Regulating Th17 Cells in a North Han Chinese Population. Front Immunol<\/em><\/strong>. 2021;12:600598. (Article, Q1, IF= 8.786)<\/p>\n\n\n\n

Zhang YM<\/strong>*, Wang YF, Rasheed H, Ott J. Editorial: Multi-Omics Study in Revealing Underlying Pathogenesis of Complex Diseases: A Translational Perspective. Front Genet<\/em><\/strong>. 2021,12:789294. (Editorial, Q1, IF=4.772)<\/p>\n\n\n\n

2020<\/strong>\u5e74<\/strong><\/strong><\/p>\n\n\n\n

Zhang YM<\/strong>. First Case of Covid-19 in the United States. N Engl J Med<\/em><\/strong>. 2020;382(21):e53. (Letter, Q1, IF= 176.079)<\/p>\n\n\n\n

Zhang YM<\/strong>#, Guo L#, Wang Z, Wang J, Er L, Barbour SJ, Trimarchi H*, Lv J*, Zhang H. External Validation of International Risk-Prediction Models of IgA Nephropathy in an Asian-Caucasian Cohort. Kidney Int Rep<\/em><\/strong>. 2020;5(10):1753-1763. (Article, Q1, IF= 6.234)<\/p>\n\n\n\n

Zhang YM<\/strong>, Zhang H*. Genetic Roadmap for Kidney Involvement of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. Clin J Am Soc Nephrol<\/em><\/strong>. 2020;15(7):1044-1046. (Review, Q1, IF= 10.614)<\/p>\n\n\n\n

Zhang YM<\/strong>#, Zheng J#*, Gaunt TR, Zhang H*. Mendelian Randomization Analysis Reveals a Causal Effect of Urinary Sodium\/Urinary Creatinine Ratio on Kidney Function in Europeans. Front Bioeng Biotechnol<\/em><\/strong>. 2020;8:662. (Article, Q1, IF= 6.064)<\/p>\n\n\n\n

Zhang YM<\/strong>#, Wang L#, Liu XZ, Zhang H*. The COVID-19 Pandemic from a Human Genetic Perspective. J Proteome Res<\/em><\/strong>. 2020;19(11):4374-4379. (Review, Q1, IF=5.370)<\/p>\n\n\n\n

Zhang YM<\/strong>, Zhou XJ, Shi SF, Liu LJ, Lyu JC, Zhang H*. Homocysteine and IgA nephropathy: observational and Mendelian randomization analyses. Chin Med J (Engl)<\/em><\/strong>. 2020;133(3):277-284. (Article, Q1, IF= 6.133)<\/p>\n\n\n\n

2019<\/strong>\u5e74<\/strong><\/strong><\/p>\n\n\n\n

\u5eb7\u7389\u7426, \u5f20\u6708\u82d7<\/strong>*, \u4faf \u5e73, \u5e08\u7d20\u82b3, \u5218\u7acb\u519b, \u5468\u7eea\u6770, \u5415\u7ee7\u6210, \u5f20 \u5b8f. IgA\u80be\u75c5\u6613\u611f\u57fa\u56e0\u9057\u4f20\u591a\u6001\u6027\u7684\u79cd\u65cf\u5dee\u5f02\u5206\u6790. \u5317\u4eac\u5927\u5b66\u5b66\u62a5\uff08\u533b\u5b66\u7248\uff09. 2019;51(03):459-466. (\u8bba\u8457, \u5317\u5927\u6838\u5fc3)<\/p>\n\n\n\n

2018<\/strong>\u5e74<\/strong><\/strong><\/p>\n\n\n\n

Zhang YM<\/strong>, Zhang H*. Insights into the Role of Mucosal Immunity in IgA Nephropathy. Clin J Am Soc Nephrol<\/em><\/strong>. 2018;13(10):1584-1586. (Review, Q1, IF= 10.614)<\/p>\n\n\n\n

Zhang YM<\/strong>, Zhang H*. Update on treatment of immunoglobulin A nephropathy. Nephrology<\/em><\/strong> (Carlton). 2018;23 Suppl 4:62-67. (Review, Q3, IF= 2.358)<\/p>\n\n\n\n

2017<\/strong>\u5e74<\/strong><\/strong><\/p>\n\n\n\n

Zhang YM<\/strong>#, Zhou XJ#, Zhang H*. What Genetics Tells Us About the Pathogenesis of IgA Nephropathy: The Role of Immune Factors and Infection. Kidney Int Rep<\/em><\/strong>. 2017;2(3):318-331. (Review, Q1, IF= 6.234)<\/p>\n\n\n\n

Zhang YM<\/strong>#, Zhou XJ#, Cheng FJ, Qi YY, Hou P, Zhao MH, Zhang H*. Association of the IKZF1 5′ UTR variant rs1456896 with lupus nephritis in a northern Han Chinese population. Scand J Rheumatol<\/em><\/strong>. 2017;46(3):210-214. (Article, Q3, IF=3.057)<\/p>\n","protected":false},"excerpt":{"rendered":"

\u8fd1\u4e94\u5e74\u5185\u7b2c\u4e00\/\u901a\u8baf\u4f5c\u8005\uff08\u542b\u5171\u540c\uff09\u53d1\u8868\u8bba\u6587\u60c5\u51b5\uff1a 2025\u5e74 Peng J, Zhang Y*, Wang J, Zhang H*, Schett G. Role of Chimeric Antigen Receptor-Expressing Cell Therapy in Immune-Mediated Kidney Diseases: A Review. Am J Kidney Dis. 2025;86(3):360-371. (Review, IF 9.4) Dang S#, Zhang X#, Zhang Y*, Zhang H*. New thoughts on the intestinal microbiome-B cell-IgA axis and therapies in IgA nephropathy. Autoimmun Rev. 2025;24(8):103835. (Review, IF 9.2) Wang J#, Xie T#, Peng J, Zhang Y*, Zhang H*. Characterizing the Real-World Risks of Kidney Injuries Associated with Chimeric Antigen Receptor T Cell Therapies-Evidence and Safety. Health Data Sci. 2025;5:0325. (Article) Zhang Z#, Wang J#, Dang S#, Liu X, Zhang Y*, Zhang H. The worldview of Akkermansia muciniphila, a bibliometric analysis. Front Microbiol. 2025;16:1500893. (Review, IF 4.0) Wang J#, Xie T#, Zhang Y*, Zhang H*. The Cardiac and Renal Safety of Semaglutide in Patients with Type 2 Diabetes: A Real-World Study Based on FAERS. Cardiorenal Med. 2025;15(1):413-422. (Article, IF 2.4) 2024\u5e74 Hu YT, Zhang YM*. Targeted release of budesonide in primary IgA nephropathy. The Lancet, 2024, 403(10446): 2785. (Letter, Q1, IF= 98.4) Wang J, Zhao W, Zhang Z, Liu X, Xie T, Wang L, Xue Y, Zhang Y*. A Journey of Challenges and Victories: A Bibliometric Worldview of Nanomedicine since the 21st Century. Adv Mater. 2024;36(15):e2308915. (Article, Q1, IF= 27.4) Wang J, Zhang Z, Liu X, Shi S, Lv J, Zhang Y*, Zhang H. Exploring Novel Adverse Events of Nefecon. Kidney Int Rep. 2024;9(9):2705-2717. (Article, Q1, IF= 5.7) Wang L, Wang J, Zhang Y*, Zhang H. Current perspectives and trends of the research on hypertensive nephropathy: a bibliometric analysis from 2000 to 2023. Ren Fail. 2024;46(1):2310122. (Article, Q1, IF= 3) Zhang YM, Zhang H. Current understanding and new insights in the treatment of IgA nephropathy. Nephrology. 2024, Suppl 2:75-79. (Review, Q2, IF= 2.4) 2023\u5e74 Zhang YM#, Liu XZ#, Zhang Z, Zhou TC, Zhang X, Yang HY, Tan M, Hu N, Shi SF, Wang F,…<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/www.yuemiaozhang.com\/index.php?rest_route=\/wp\/v2\/pages\/115"}],"collection":[{"href":"https:\/\/www.yuemiaozhang.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.yuemiaozhang.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.yuemiaozhang.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.yuemiaozhang.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=115"}],"version-history":[{"count":17,"href":"https:\/\/www.yuemiaozhang.com\/index.php?rest_route=\/wp\/v2\/pages\/115\/revisions"}],"predecessor-version":[{"id":257,"href":"https:\/\/www.yuemiaozhang.com\/index.php?rest_route=\/wp\/v2\/pages\/115\/revisions\/257"}],"wp:attachment":[{"href":"https:\/\/www.yuemiaozhang.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}